Charmaine Kim-Sing, MB ChB FRCPC
University of British Columbia (UBC)
Active Staff: Radiation Oncologist
British Columbia Cancer Agency (BCCA) – Vancouver Centre *
Consulting Staff: Vancouver General Hospital
Hospital Authority: Provincial Health Services
600 West 10th Avenue
Vancouver, BC V5Z 4E6
Phone: 604.877.6000 Fax: 604.877.0505
Major Clinical Focus – Genitourinary cancer (high risk prostate cancer) and Skin cancer
• University of Cape Town Faculty of Medicine, South Africa, 1980
• Fellow of The Royal College of Physicians of Canada, 1991
• Fellow (Radiation Oncology), BCCA, Vancouver 1990-1991
• Radiation Oncology residency BCCA Vancouver 1983-1984, 1989-1990
Biographic Summary ( Background, Academic Interests and Activities, Clinical Activities )
Medical Leader Hereditary Cancer Program 1998-2005
Director Hereditary Cancer Program 2006-2008
President British Columbia Association of Radiation Oncologists 1999-2001
Chair Medical Advisory Committee 2001-2003
Member Board of Trustees BC Cancer Agency 2001-2002
Skin Tumour Group Chair 2003-2006
Dr May Cohen Award from the Federation of Medical Women for the Promotion of Women’s Health August 2000
Canadian Breast Cancer Foundation Professional Achievement Award 2003
Dr Kim-Sing has been actively involved in teaching and mentoring the next generation of medical students and physicians. She has also focussed on public education in breast cancer, cancer prevention and early detection and hereditary cancer syndromes. She has written pamphlets, resource handbooks, book chapters and developed educational videos.
Dr Kim-Sing’s research interests include cancer communication and hereditary cancer.
PUBLICATIONS ( 9 selected from 55 peer reviewed publications )
1. Tyldesley S, Peacock M, Morris WJ, So Alan, Kim-Sing C, Quirt J, Carter M, Pickles T. Department of Radiation Oncology, Vancouver Cancer Centre, Vancouver, Canada. The need for, and utilization of radiotherapy after radical prostatectomy for patients with prostate cancer in British Columbia. 2011. CUAJ.
2. Metcalfe K, Lubinski J, Lynch HT, Ghadirian P, Foulkes WD, Kim-Sing C, Neuhausen S, Tung N, Rosen B, Gronwald J, Ainsworth P, Sweet K, Eisen A, Sun P, Narod SA. Hereditary Breast Cancer Clinical Study Group. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. Journal of the National Cancer Institute. 2010 Dec 15. 102(24):1874-8.
3. Thorne S, Oliffe J, Kim-Sing C, Hislop TG, Stajduhar K, Harris SR, Armstrong EA, Oglov V. Helpful communications during the diagnostic period: an interpretive description of patient preferences. European Journal of Cancer Care. 2010 Nov. 19(6):746-54.
4. Horsman D, Wilson BJ, Avard D, Meschino WS, Kim-Sing C, Plante M, Eisen A, Howley HR, Simard J; National Hereditary Cancer Task Force. Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. J Obstet Gynaecol Can. 2007 Jan;29(1):45-60.
5. Kim-Sing C, Weir L, Kuusk U. Breast cancer risk management for moderate-risk and high risk women. BCMJ, vol46 No. 8, pp405-409,2004.
6. Kim-Sing C, Pickles T; Prostate Cohort Outcomes Initiative. Intervention after PSA failure: examination of intervention time and subsequent outcomes from a prospective patient database. Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):463-9.
7. Pickles T, Kim-Sing C, Morris WJ, Tyldesley S, Paltiel C. Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):11-8.
8. Gelmon KA, Kim-Sing C. Hormone Therapy and Breast Cancer. BCMJ 2001 Nov 43(9):511-16.
9. Voss N, Kim-Sing C. Radiotherapy in the treatment of dermatologic malignancies. Dermatol Clin. 1998 Apr;16(2):313-20.
* The British Columbia Cancer Agency (BCCA)-Vancouver Centre (VC) is the largest academic cancer centre for the BCCA, located in downtown Vancouver and treating about one third of the radiation oncology cancer patients in the Province of BC. Over 4360 cancer patients are seen each year in the radiation oncology department. There are 20 Radiation Oncology (RO) physician faculty with full disease site specialization and clinical programs of excellence, 2 General Practice (Internist) Oncology Physicians, 3 Clinical Fellows and 10 RO residents. The BCCA-Vancouver Centre also has 17 physicists and a graduate training program in physics, 15 nurses, >60 radiation therapists clerks, secretaries and many others within radiation oncology. General capabilities include 9 Linacs (including Truebeam), 1 cobalt, VMAT (first developed in the BCCA-VC), IMRT, SBRT, IGRT, HDR and LDR brachytherapy suites, and Protons (at the TRIUMF centre). The Vancouver Centre radiation oncology department conducts all levels of research (basic, translational, clinical, population), and is the main educational institution in BC for the training of graduate (residents) and undergraduate (medical) students. The interdisciplinary Radiation Oncology team is part of the even larger multidisciplinary and provincial teams.